Price
Target price
€1.91
€1.91
-3.170%
-0.0555
-3.170%
€4.62
19.04.24 / Tradegate
WKN: A0LC2W / Symbol: EBS / Name: Emergent Bio / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Emergent Biosolutions Inc. Stock
Heavy losses for Emergent Biosolutions Inc. today as the stock fell by -€0.056 (-3.170%).
With 2 Buy predictions and 3 Sell predictions the community is currently undecided on Emergent Biosolutions Inc..
However, we have a potential of 109.42% for Emergent Biosolutions Inc. as the target price of 4 € is above the current price of 1.91 €.
For the coming years our community has positive and negative things to say abot the Emergent Biosolutions Inc. stock. Criterium "Company culture" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Emergent Biosolutions Inc. in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Emergent Biosolutions Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc. | -3.170% | -1.622% | -15.859% | -80.823% | -14.273% | -96.613% | -95.861% |
| Iovance Biotherapeutics Inc. | -3.130% | -8.480% | -17.018% | 99.213% | 36.142% | -58.428% | - |
| Novocure Ltd | -1.720% | -11.085% | -8.909% | -80.445% | -20.490% | -92.848% | - |
| Fibrogen Inc. | -6.530% | -12.429% | -50.711% | -94.254% | 24.942% | -93.189% | - |
Comments
Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $5.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) was upgraded by analysts at Benchmark Co. from a "hold" rating to a "buy" rating. They now have a $5.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat
Emergent BioSolutions Inc. (NYSE: EBS) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co..
Show more
Ratings data for EBS provided by MarketBeat
